• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
AIDS - Related Lymphoma - Pipeline Review, H1 2012 Product Image

AIDS - Related Lymphoma - Pipeline Review, H1 2012

  • Published: January 2012
  • 90 pages
  • Global Markets Direct

AIDS - Related Lymphoma – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'AIDS - Related Lymphoma - Pipeline Review, H1 2012', provides an overview of the AIDS - Related Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for AIDS - Related Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for AIDS - Related Lymphoma. 'AIDS - Related Lymphoma - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for AIDS - Related Lymphoma.
- A review of the AIDS - Related Lymphoma products under development READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
AIDS - Related Lymphoma Overview
Therapeutics Development
An Overview of Pipeline Products for AIDS - Related Lymphoma
AIDS - Related Lymphoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
AIDS - Related Lymphoma Therapeutics – Products under Investigation by Universities/Institutes
AIDS - Related Lymphoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Bryostatin 1 + Vincristine - Drug Profile
Doxil + Methotrexate + Prednisone + Vincristine Sulfate + Sargramostim - Drug Profile
Aldesleukin + Recombinant Human Stem Cell Factor - Drug Profile
Aldesleukin + Ganciclovir + Zidovudine - Drug Profile
cART + R-EPOCH - Drug Profile
Methotrexate + Zidovudine + Radiation Therapy - Drug Profile
Filgrastim + Cyclophosphamide + Cytarabine + Methotrexate + Pegylated Liposomal Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate + Radiation Therapy - Drug Profile
BCNU + Etoposide + Cytarabine + Melphalan + Autologous Hematopoietic Cell Transplantation - Drug Profile
EPOCH Regimen + Methotrexate + Prednisone + Cytarabine + Filgrastim - Drug Profile
EPOCH Regimen + Methotrexate + Prednisone + Cytarabine + Filgrastim - Drug Profile
Filgrastim + Pegfilgrastim + Rituximab + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Leucovorin Calcium + Liposomal Cytarabine + Methotrexate + Therapeutic Hydrocortisone + Vincristine Sulfate - Drug Profile
Methotrexate + rituximab - Drug Profile
Filgrastim + Rituximab + Cyclophosphamide + Doxorubicin Hydrochloride + Prednisone + Vincristine Sulfate - Drug Profile
R-EPOCH + cART - Drug Profile
Sunitinib - Drug Profile
Filgrastim + Cyclophosphamide + Etoposide + Lomustine + Procarbazine Hydrochloride - Drug Profile
Filgrastim + Lomustine + Procarbazine Hydrochloride + Radiation Therapy - Drug Profile
Bleomycin Sulfate + Filgrastim + Cyclophosphamide + Cytarabine + Doxorubicin Hydrochloride + Etoposide + Leucovorin Calcium + Methotrexate + Prednisone + Trimethoprim-Sulfamethoxazole + Vincristine Sulfate + Radiation Therapy - Drug Profile
Bleomycin - Drug Profile
EPOCH + Rituximab - Drug Profile
Filgrastim + Rituximab + Sargramostim + Cyclophosphamide + Doxil + Prednisone + Vincristine Sulfate - Drug Profile
Rituximab + EPOCH - Drug Profile
Rituximab + EPOCH + Vorinostat - Drug Profile
R-CHOP - Drug Profile
R-CHOP + Vorinostat - Drug Profile
Etoposide + Methylprednisolone Sodium Succinate + Carboplatin + AraC + Rituximab + MCNU + L-PAM + Autologous Peripheral Blood Stem Cell Transplantation - Drug Profile
CHOP + Rituximab + Peripheral Blood Stem Cell Transplantation - Drug Profile
HAART + Methotrexate + Rituximab + Leucovorin - Drug Profile
Velcade + Carboplatin + Dexamethasone + Etoposide + Ifosfamide - Drug Profile
Fludarabine + Busulfan + Melphalan + Cyclophosphamide + Total Body Irradiation + Allogeneic Hematopoietic Cell Transplantation - Drug Profile
AIDS - Related Lymphoma Therapeutics – Discontinued Products
AIDS - Related Lymphoma Therapeutics - Dormant Products
Appendix
Methodology
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for AIDS - Related Lymphoma, H1 2012
Products under Development for AIDS - Related Lymphoma – Comparative Analysis, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
AIDS - Related Lymphoma Therapeutics – Discontinued Products
AIDS - Related Lymphoma Therapeutics – Dormant Products

List of Figures
Number of Products under Development for AIDS - Related Lymphoma, H1 2012
Products under Development for AIDS - Related Lymphoma – Comparative Analysis, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos